泽璟制药(688266) - 2020 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders was -CNY 62,262,940.60, an improvement from -CNY 170,132,628.57 year-on-year[11] - Basic and diluted earnings per share were both -CNY 0.28, improving from -CNY 0.95 in the same period last year[11] - The company reported a net loss of CNY -534,591,670.93, compared to a loss of CNY -472,328,730.33 in the previous period[34] - Total operating revenue for Q1 2020 was significantly lower at 73,021,269.57 compared to 177,045,064.17 in Q1 2019, indicating a decline of approximately 58.8%[46] - Net profit for Q1 2020 was reported at -65,385,205.55, a decrease from -172,644,238.60 in Q1 2019, reflecting an improvement of about 62.1%[47] - Total comprehensive income for Q1 2020 was -63,233,146.26, an improvement from -174,772,723.78 in Q1 2019, reflecting a reduction in losses of approximately 63.8%[47] Assets and Liabilities - Total assets increased by 559.82% to CNY 2,113,204,454.12 compared to the end of the previous year[11] - Total liabilities decreased to CNY 186,190,824.88 from CNY 246,517,910.69, a decline of approximately 24.5%[34] - Current liabilities decreased to CNY 90,474,299.90 from CNY 150,168,166.60, showing a reduction of about 39.8%[33] - Non-current assets totaled CNY 229,907,758.80, up from CNY 218,443,968.60, reflecting a rise of approximately 6.3%[33] - Owner's equity increased to CNY 1,927,013,629.24 from CNY 73,750,177.00, representing a substantial increase[34] Cash Flow - Net cash flow from operating activities was -CNY 77,046,755.90, worsening from -CNY 42,189,296.87 in the same period last year[11] - The net increase in cash and cash equivalents was 1,032,654,939.89 RMB, compared to a decrease of -6,354,594.56 RMB in the same quarter last year[59] - Total cash inflow from financing activities reached 1,944,320,000.00 RMB, significantly higher than 20,000,000.00 RMB in the previous year[60] - Cash outflow from investing activities totaled 749,372,922.94 RMB, compared to 60,018,691.01 RMB in the same quarter last year[57] - The cash balance at the end of the period was 1,099,575,161.65 RMB, up from 122,577,713.08 RMB in the previous year[59] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,329[17] - The largest shareholder, ZELIN SHENG, holds 20.68% of the shares, totaling 49,636,620 shares[17] - The total equity attributable to shareholders reached CNY 1,858,758,753.15, a significant increase from CNY 3,426,155.64[34] Research and Development - Research and development expenses increased by 66.32% to ¥60,519,772.20, related to clinical trial projects[24] - Research and development expenses as a percentage of operating income were not applicable for this period[11] Other Income and Expenses - Non-recurring gains and losses included government subsidies of CNY 4,822,563.38 and bank wealth management income of CNY 1,732,334.04[15] - Total revenue from other income increased by 76.60% to ¥4,822,564.11, reflecting new government subsidies[24] - Management expenses decreased by 89.49% to ¥14,715,362.29, primarily due to a reduction in share-based payment expenses[24] - The company experienced a financial expense of -6,464,578.12 in Q1 2020, a significant decrease from 514,777.16 in Q1 2019, indicating a reduction in financial costs[46] - Tax expenses for Q1 2020 were reported at 136,823.86, slightly lower than 143,314.34 in Q1 2019, showing a decrease of about 4.5%[46] Future Outlook - The company expects to continue incurring losses until at least the next reporting period due to the absence of drug sales[26] - The company has not applied the new revenue and lease standards starting from 2020[62] - There are no retrospective adjustments for prior comparative data related to the new revenue and lease standards[62] - The audit report is not applicable for the current financial period[62]